Foghorn Therapeutics Q1 net loss narrows to $18.8M; pipeline advances with FHD-909 Phase 1 and degrader programs

Foghorn Therapeutics Inc.

2025-Q1 EPS reported -$0.30 revenue$5,952,000

Q1 2025 net loss $18.8M vs $25.0M in Q1 2024; collaboration revenue $6.0M (up from $5.1M).
Cash, equivalents, and marketable securities $220.6M; cash runway into 2027.
FHD-909 (SMARCA2 inhibitor) Phase 1 dose escalation in SMARCA4-mutated cancers ongoing, NSCLC primary target.
Selective CBP degrader targeting IND in 2026; ARID1B and EP300 degrader program updates expected H2 2025.
Board appointments: Neil Gallagher (Syndax President) and Stuart Duty (former Guggenheim Senior MD) in May 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.